We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Avacta Group Plc | AVCT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 3.80 | 8.44% | 48.80 | 16:35:17 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 45.00 | 45.00 | 49.00 | 48.80 | 45.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 22/4/2024 17:21 by pwhite73 "Death spiral financing is the result of a badly structured convertible financing used to fund primarily small cap companies in the marketplace, causing the company's stock to fall dramatically, which can lead to the company's ultimate downfall."Capitalised at £250 million in October 2022 when the loan was taken out AVCT were not what you could call a small cap company. |
Posted at 13/4/2024 09:00 by mirabeau AVCT-ce to Go! Collect £200The Avacta Phase 1a read out is compelling ======= It's a hefty read but superb analysis from The Oak Bloke, thanks to him |
Posted at 28/2/2024 09:42 by loglorry1 There won't be a license agreement. There has been zero industry interest in AVCT. Retail haven't got the firepower to fund this as AVCT need £20m at least. I can't see an institution putting money in this while the death spiral remains. Not sure what their options are at this point maybe a bigger death spiral? |
Posted at 27/2/2024 21:29 by papillon Once that Strongly Bearish H&S pattern formed on the AVCT chart recently at 100p that just confirmed the bearish Ichimoku chart and you knew then, Dudishes, that there was no way back for the AVCT sp |
Posted at 22/2/2024 13:38 by loglorry1 I'm probably being a drama queen but what if AVCT simply can't raise the tens of millions of pounds needed to progress? What then? What have they got which is worth so much?It seems to me that the bulls think it is a forgone conclusion that they can raise funds but this isn't some needing to raise £2m to keep the lights on they need some quite serious capital. We have seen with FARN recently having failed to raise and the lender taking control of their bank account caused the shares to crater. If FARN can't raise then why do you think AVCT can. |
Posted at 19/2/2024 09:54 by loglorry1 Well I think we have to disagree on that one PWhite. Certain industries are much easier to understand than others. There are much easier competitor evacuations, commodity price read across, JV valuations, tangible asset evaluations, visisble TAM, take over valuations, dividend and p/e ratios, the list goes on. With AVCT you are 100% buying an intangible asset which is the claims that the management are making and you have no way to know if they are true or not.With CINE you claimed to have in depth knowledge of the complex court proceedings which to most people made no common sense. You were 100% wrong and were shown to be. I suspect AVCT is much more complex than that. I'm not saying you are wrong about AVCT having substantially less IP backing than they claim. I'm just saying nobody here can really say either way. |
Posted at 14/12/2023 07:35 by tickboo Rah on X-Digesting the reaction to yesterday's PK is even more absurd in the cold light of day. #AVCT has:- demonstrated unequivocally that preCISION works;- delivered Dox into the tumour in a highly specific way, sparing healthy tissue in the process, solving a 50 yr old problem in the process;- shown a 65% reduction in a patient with STS, who would not be expected to live, let alone remain on drug for 15 months as is their expectation;- demonstrated other refractory cancers are showing a halting of progression and/or shrinkage.Dox is being dox. But much, much safer. It's the exact problem AVCT set out to solve before the trial began 856 days ago when the share price sat at 124p.We should be sat at ATHs right now. The product works. The platform works.Why aren't we? The CEO opted to shy away from every question on funding, beyond confirmation we will not seek to partner our lead asset til P2 (sensible).It's quite clear there is tons going on right now which AVCT simply refuse to talk to.The conversations which were happening in June ('deal value discussions') haven't just gone way; Novartis employees aren't publicly lauding our achievement to be nice; the CEO didn't utter a word on funding because it slipped his mind.AVCT will next take a working drug and dose on a a bi-weekly basis. Dox will be dox. And dox is the 40yr old standard of care in STS. How do you think Dox will perform when placed in patients via a 1st line setting? It will do as Dox always does.AVCT will not require a dox comparison arm in Phase 2. Avacta will skip Phase 1b. They will seek Accelerated Approval. We know how Dox works. We know we can deliver it safely. We know Pharma is watching.The share price has fallen from 124p > 118p over this period.Few doubts given all of the above a deal lands, independently verifying the platform. When that occurs the whiplash will be severe.I'm not saying the CEO's ambivalence to the share price is acceptable. It's not. I'm saying I think he has something up his sleeve which rendered him almost horizontal in his confidence. Good luck if you're playing 7am roulette with a working platform, backed by 850+ days of data. A risky time to be doing that. |
Posted at 01/11/2023 08:57 by tickboo https://twitter.com/ |
Posted at 20/9/2023 08:11 by tickboo Worth a re-post -This morning’s #AVCT RNS was Andy Dufresne out of the sewer pipe and basking in the rain. No shortage of information to unpack, which should not be a surprise given AVCT is sat on 25 months of detailed data. Firstly, safety: An “excellent safety profile continues to be observed in the sixth dose escalation cohort” At 310mg of Dox, 209mg of AVA6000 equivalent (but targeted and therefore super charged) AVA6000 continues to be received safely. That statement alone changes the landscape of Doxorubicin. It can be dosed for longer, drastically expanding the number of people who can receive it, thereby enabling the efficacy of Doxorubicin to be utilised. It becomes the standard of care overnight. Worth remembering Lartruvo hit sales of $562m per quarter (per quarter) before it was found to be no better than Doxorubicin alone. We do not have that problem, AVA6000 is doxorubicin. The market continues to misunderstand this simple fact. This is the ‘small’ market we will initially target: $2Bn+ per year. Next up, efficacy, a “significant reduction in tumour volume confirmed in a patient with soft tissue sarcoma” A significant reduction in tumour volume. It is working. Let’s put to bed this absurd concept that AVCT may not have a working delivery platform. It works. And it’s unbelievably safe. It’s also worth bearing in mind the criteria for inclusion in P1a. These are very sick (selfless) patients. To observe a halting of disease profession is one thing, to observe a significant reduction is something else. I note AVCT explicitly did not choose to define the reaction in RECIST terms. Does a significant response equate to complete response? I suspect not, but I’m assuming they’re very close and patients in Cohort 6 are only 2-4 doses into trial. What will dose 5 and 6 deliver? We will know soon enough with detailed data being released in Q4. Again, I thought they would hold this back to AACR 2024 so a win. Specifics aside, AVCT now has what pharma have been craving: efficacy. Partnerships will follow. It’s also worth observing AVCT had authority to go to C7 (at 400mg). The fact they are not (and have selected 385mg) demonstrates they’ve finally found the sweet spot on the response Vs safety curve. Next, the most significant statement to date (given we knew it was efficacious): A “revised regulatory strategy aims to achieve earlier commencement of pivotal Phase 2 study in soft tissue sarcoma in 2024” Avacta have turned their plan on its head. The FDA - not the MHRA is now in the driving seat - which is fabulous news. They are remarkably quick. They know Tap. They know Lartruvo. They know Dox. An accelerate approval application is almost certainly coming. They want to expedite safe drugs. Side note: pulling that LFT a master stroke in the grand scheme of relationship with the FDA. Crucially, this trial is no longer late. It’s ahead of schedule. Find me a Phase 2 clinical drug which is efficacious and shown zero reaction in share price over a 25 month period. The muted reaction is of course the elephant in the room: funding. However, AVCT will have zero problem achieving funding. They will now have a plethora of options too: from licensing the pipeline to an exclusive placement with a serious II. The share price is suggestive the open market will be invited to this funding event. It won’t be. We’re therefore in a perverse position where I suspect a funding RNS will move the dial more than succeeding where pharma have failed for 50 years. Even without funding, an share price sub ATHs is demonstrative the market still doesn’t get it. An share price below where it was before the trial began is quite frankly laughable. AVCT will shortly be a phase 2 clinical trial company where the sums of its parts is lower than before this trail began. Andy will be on the beach soon, mending boats with Red. Well done to all SHs who kept the faith: an unwavering little community here. Most think we’re mad. Then again, most would have sold keytruda for $1,000. |
Posted at 19/9/2023 12:23 by tickboo From RAH -This morning’s #AVCT RNS was Andy Dufresne out of the sewer pipe and basking in the rain. No shortage of information to unpack, which should not be a surprise given AVCT is sat on 25 months of detailed data. Firstly, safety: An “excellent safety profile continues to be observed in the sixth dose escalation cohort” At 310mg of Dox, 209mg of AVA6000 equivalent (but targeted and therefore super charged) AVA6000 continues to be received safely. That statement alone changes the landscape of Doxorubicin. It can be dosed for longer, drastically expanding the number of people who can receive it, thereby enabling the efficacy of Doxorubicin to be utilised. It becomes the standard of care overnight. Worth remembering Lartruvo hit sales of $562m per quarter (per quarter) before it was found to be no better than Doxorubicin alone. We do not have that problem, AVA6000 is doxorubicin. The market continues to misunderstand this simple fact. This is the ‘small’ market we will initially target: $2Bn+ per year. Next up, efficacy, a “significant reduction in tumour volume confirmed in a patient with soft tissue sarcoma” A significant reduction in tumour volume. It is working. Let’s put to bed this absurd concept that AVCT may not have a working delivery platform. It works. And it’s unbelievably safe. It’s also worth bearing in mind the criteria for inclusion in P1a. These are very sick (selfless) patients. To observe a halting of disease profession is one thing, to observe a significant reduction is something else. I note AVCT explicitly did not choose to define the reaction in RECIST terms. Does a significant response equate to complete response? I suspect not, but I’m assuming they’re very close and patients in Cohort 6 are only 2-4 doses into trial. What will dose 5 and 6 deliver? We will know soon enough with detailed data being released in Q4. Again, I thought they would hold this back to AACR 2024 so a win. Specifics aside, AVCT now has what pharma have been craving: efficacy. Partnerships will follow. It’s also worth observing AVCT had authority to go to C7 (at 400mg). The fact they are not (and have selected 385mg) demonstrates they’ve finally found the sweet spot on the response Vs safety curve. Next, the most significant statement to date (given we knew it was efficacious): A “revised regulatory strategy aims to achieve earlier commencement of pivotal Phase 2 study in soft tissue sarcoma in 2024” Avacta have turned their plan on its head. The FDA - not the MHRA is now in the driving seat - which is fabulous news. They are remarkably quick. They know Tap. They know Lartruvo. They know Dox. An accelerate approval application is almost certainly coming. They want to expedite safe drugs. Side note: pulling that LFT a master stroke in the grand scheme of relationship with the FDA. Crucially, this trial is no longer late. It’s ahead of schedule. Find me a Phase 2 clinical drug which is efficacious and shown zero reaction in share price over a 25 month period. The muted reaction is of course the elephant in the room: funding. However, AVCT will have zero problem achieving funding. They will now have a plethora of options too: from licensing the pipeline to an exclusive placement with a serious II. The share price is suggestive the open market will be invited to this funding event. It won’t be. We’re therefore in a perverse position where I suspect a funding RNS will move the dial more than succeeding where pharma have failed for 50 years. Even without funding, an share price sub ATHs is demonstrative the market still doesn’t get it. An share price below where it was before the trial began is quite frankly laughable. AVCT will shortly be a phase 2 clinical trial company where the sums of its parts is lower than before this trail began. Andy will be on the beach soon, mending boats with Red. Well done to all SHs who kept the faith: an unwavering little community here. Most think we’re mad. Then again, most would have sold keytruda for $1,000. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
